NCT00310635View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

PHASE4CompletedINTERVENTIONAL

Enrollment

241

Participants

Timeline

Start Date

June 30, 2005

Conditions

Meningococcal Infection

Interventions

BIOLOGICAL

Meningococcal C conjugate vaccine

Trial Locations (1)

Unknown

Mainz, Kehl, Traunreut, Mühldorf am Inn, Bad Sobernheim, Bad Kreuznach, Baldham, Speyer,, Oppenheim

Sponsors

Lead Sponsor

Collaborators (1)

Novartis Vaccines

All Listed Sponsors

collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY

NCT00310635 - Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age | Biotech Hunter | Biotech Hunter